Vitality Watch

Dossier pubmed review 12-jul-2026
Narrative review or expert overview without new data

Biological limits of lifespan extension: Evidence for a shift from pathway leverage to system-level buffering across species.

Key claim: Lifespan-extension interventions targeting conserved pathways lose efficacy as organismal complexity rises because aging shifts from a few high-leverage pathways in simple models to redundant, multi-tissue systems with feedback and competing constraints in mammals.

Abstract

Interventions targeting conserved aging pathways can markedly extend lifespan in model organisms, yet their efficacy declines with increasing organismal complexity. While this phenomenon is well documented, the underlying constraints remain poorly defined. Here, we integrate comparative experimental data with mechanistic insights to propose a unifying framework explaining the declining ceiling of lifespan extension. We show that in simple organisms, aging is governed by a limited number of high-leverage pathways, whereas in mammals it emerges from distributed, multi-tissue regulatory systems characterized by redundancy, feedback, and competing physiological constraints. By synthesizing findings from Caenorhabditis elegans, Drosophila melanogaster, and rodent models, we identify key determinants of this transition, including metabolic organization, genetic redundancy, endocrine regulation, microbiome interactions, and pharmacokinetic complexity.

Why this matters

Most geroscience interventions enter human trials off the back of large single-pathway lifespan gains in worms, flies, or short-lived mice. This synthesis sharpens the long-standing observation that those effect sizes shrink with complexity into a mechanistic claim — that aging in mammals is a distributed, redundantly-buffered system — which, if correct, predicts that no single conserved-pathway lever (mTOR, IIS, sirtuin, AMPK) will reproduce invertebrate-scale lifespan extension in humans, and reframes what ‘translation’ from model organisms can realistically mean.

Source

Link

Briefing card

Biological limits of lifespan extension: Evidence for a shift from pathway leverage to system-level buffering across species.
Stage: review · pubmed · 12-jul-2026

If you follow pathway-targeted longevity drugs (rapamycin, metformin, sirtuin activators) based on worm or fly lifespan numbers, this framework argues the mammalian ceiling for any single-pathway intervention is structurally smaller than those headline effect sizes.

Lifespan-extension interventions targeting conserved pathways lose efficacy as organismal complexity rises because aging shifts from a few high-leverage pathways in simple models to redundant, multi-tissue systems with feedback and competing constraints in mammals.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.mad.2026.112231

build build 880 · 2bcef25 · 2026-11-18